Taken together, these data strongly demonstrate the crucial and potent pro-metastatic role of VAL in constitutively activated AKT-driven LAD metastasis and a great therapeutic potential of targeting VAL for metastatic LAD patients. This evidence concerns the gene AKT1 and leukocyte adhesion deficiency.